Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Healthy
Interventions
DRUG

Atipamezole

Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion

DRUG

Atomoxetine

A single dose of 1.2 mg/kg of atomoxetine administered orally

DRUG

Ketamine

A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion

OTHER

Cold pressor test

30-45 min cold pressor test of the foot

DRUG

Insulin

Insulin administered as an intravenous infusion to induce hypoglycemia

DRUG

Placebo

A single dose of placebo (capsules) administered orally

Trial Locations (2)

20520

University of Turku, Clinical Research Services Turku CRST, Turku

University of Turku, Turku PET Centre, Turku

All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

University of Turku

OTHER

NCT01435213 - Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline | Biotech Hunter | Biotech Hunter